Galapagos Puts Faith In Refocused Pipeline To Regain Investor Confidence

After High-Profile Setbacks In The Clinic

The Belgian biotech's president, Bart Filius, tells Scrip that exiting the metabolic disease and osteoarthritis space and focusing on inflammation makes sense to "bring a bit more balance in terms of risk into our portfolio."

filius bart
Bart Filius • Source: Galapagos

After a very tough nine months, Galapagos NV has laid the foundations on the road to recovery by refocusing its research areas, targeting €150m in savings and seeking out late-stage assets to fill the gap between its approved rheumatoid arthritis drug Jyseleca and the rest of the pipeline.

Bart Filius, Galapagos president, mapped out the Belgian biotech's strategy to Scrip after the completion of a review of the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Leadership

More from Scrip